Regulatory Norgine gets first EU approval for WHIM syndrome therapy PharmaphorumPatients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.Rare DiseaseRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine’s Xolremdi. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Regeneron Q1 2026 net income falls 10% to $727mNext: GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
